News Search Results
Aug 01, 2025, 07:00 ET Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
significant unmet need, including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. In addition, the generics and sterile injectables business features a broad product portfolio, a
More news about: Mallinckrodt plc
Jul 31, 2025, 10:45 ET Contract Research Organization Market is Poised to Reach USD 122.2 Billion by 2032 | SkyQuest Technology Consulting
site into one, easy-to-use dashboard.In September 2024, A new contract research organization solution for ophthalmology clinical trials was launched by Lindus Health. The new solution can handle vast amounts of data generated from clinical trials to enhance the operation
More news about: SkyQuest Technology
Jul 31, 2025, 09:10 ET AEYE Health Appoints Renowned Ophthalmologist Dr. Pamela F. Gallin as Chief Medical Officer to Support AEYE-DS' Rapid US Expansion
a Clinical Professor of Ophthalmology in Pediatrics at the Morgan Stanley Children's Hospital of NewYork-Presbyterian and The Edward S. Harkness Eye Institute at Columbia University Medical Center. She is Director Emeritus of Pediatric Ophthalmology and Adult Strabismus at
More news about: AEYE Health
Jul 30, 2025, 10:30 ET Biosimilars Market is Estimated to Reach USD 88.9 Billion by 2032 | SkyQuest Technology Consulting
February 2025. The biosimilar increases competition with Bayer/Regeneron's Eylea in international healthcare markets and broadens Amgen's ophthalmology portfolio.Sandoz entered the osteoporosis and oncology biosimilars market in March 2024 after the FDA approved
More news about: SkyQuest Technology
Jul 30, 2025, 07:00 ET InMode Reports Second Quarter 2025 Financial Results: Quarterly Revenue of $95.6 Million, 80% Gross Margins
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
More news about: InMode Ltd.
Jul 29, 2025, 15:01 ET AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
Latin America. In June, Vargas was featured at Roche's "Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent
More news about: Equity Insider
Jul 29, 2025, 10:30 ET Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting
endothelial disease in the second half of 2025. Aurion will also benefit from Alcon's extensive resources in R&D, regulatory, medical, and commercial ophthalmology. In March 2025, YASKAWA Electric Corporation and Astellas Pharma Inc. signed a final agreement to create
More news about: SkyQuest Technology
Jul 29, 2025, 01:00 ET Bascom Palmer Remains No. 1 in 2025 U.S. News & World Report Rankings
24th year, Bascom Palmer Eye Institute, part of UHealth – University of Miami Health System, is the No. 1 ophthalmology hospital in the U.S., according to the newly released 2025
More news about: University of Miami Health System
Jul 28, 2025, 15:05 ET Piramal Pharma Limited Announces Results for Q1FY26
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Jul 28, 2025, 15:01 ET Piramal Pharma Limited Announces Results for Q1FY26
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Jul 28, 2025, 00:00 ET Dômes Pharma Teams Up with Fear Free to Make Eye Care Less Stressful for Pets
CITY, July 28, 2025 /PRNewswire/ -- Dômes Pharma, a global leader in veterinary ophthalmology solutions, is proud to announce its strategic alliance with Fear Free®, joining the Fear Free Preferred Product Program. This collaboration recognizes
More news about: Dômes Pharma, Inc.
Jul 24, 2025, 10:01 ET Patient Registry Software Market worth $3.61 billion by 2030 with 9.8% CAGR | MarketsandMarkets™
registries, asthma registries, chronic kidney disease registries, and orthopaedic registries. There are also registries for other conditions, including ophthalmology, hemophilia, COVID-19, and neuromuscular diseases. In 2025, the disease registries segment held the largest share of the patient registry
More news about: MarketsandMarkets
Jul 24, 2025, 10:00 ET Tarsier Pharma: New Data Reveal Sharp Rise in Vision Loss from Uveitis, Underscoring Urgent Need for Safer Treatments
backdrop of this robust and overwhelming data." Dr. Meghan Berkenstock, last author of the American Journal of Ophthalmology publication, added: "Our extensive study not only demonstrated that the prevalence of uveitis is much higher than previously believed but
More news about: Tarsier Pharma
Jul 22, 2025, 09:15 ET From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
platform, with Ainnova CEO Vinicio Vargas recently featured as a speaker at Roche's "Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia. The event brought together leading voices in visual health from across
More news about: USA News Group
Jul 22, 2025, 08:45 ET Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion
More news about: MarketNewsUpdates
Jul 22, 2025, 08:00 ET Avant Technologies' Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
(CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Cartagena, Colombia.
More news about: Avant Technologies Inc.
Jul 22, 2025, 06:45 ET Mallinckrodt plc to Report Earnings Results for Second Quarter 2025
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Jul 21, 2025, 06:58 ET Orbis International Brings the Flying Eye Hospital to Rwanda for the First Time to Train Local Eye Care Teams
project—which is supported by corporate sponsors the Alcon Foundation and OMEGA and hosted in partnership with the Rwanda International Institute of Ophthalmology (RIIO) and Kibagabaga Hospital—aims to build the skills of local eye care teams, raise awareness about eye health, and expand lasting access to
More news about: Orbis International
Jul 17, 2025, 13:12 ET CoVet Forms Groundbreaking Specialty Advisory Board to Guide Future of Veterinary AI
ethical application of AI, specialty workflows, and new product innovation. "Veterinary specialties, from cardiology to internal medicine to ophthalmology, have unique clinical workflows and documentation challenges that general-purpose tools often overlook," said Dr. Mike Mossop,
More news about: CoVet
Jul 17, 2025, 07:43 ET Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc.
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Jul 17, 2025, 05:00 ET Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
"Pharmacovigilance on dexamethasone 1mg/mL + levofloxacin 5 mg/mL eye drops, solution: a five-year registry.", was conducted by experts in ophthalmology and drug safety.
More news about: NTC Srl
Jul 17, 2025, 05:00 ET Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
"Pharmacovigilance on dexamethasone 1mg/mL + levofloxacin 5 mg/mL eye drops, solution: a five-year registry.", was conducted by experts in ophthalmology and drug safety.
More news about: NTC Srl
Jul 17, 2025, 00:00 ET Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Jul 16, 2025, 20:00 ET Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an
More news about: Innovent Biologics
Jul 16, 2025, 03:14 ET TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model
Marcia Swank, Vice President and Head of Ophthalmology, who has shaped the unit into a focused partner for companies developing therapies and devices for eye conditions. "In ophthalmology, every day counts for sponsors racing to innovate, and for patients waiting
More news about: TFS HealthScience